Document Detail


A comparison of preferences for two GLP-1 products--liraglutide and exenatide--for the treatment of type 2 diabetes.
MedLine Citation:
PMID:  21034377     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To use time trade-off (TTO) to compare patient preferences for profiles of two glucagon-like peptide (GLP-1) products for the treatment of type 2 diabetes (liraglutide and exenatide) that vary on four key attributes - efficacy (as measured by hemoglobin A(1C)), incidence of nausea, incidence of hypoglycemia, and dosing frequency (QD vs. BID) - and measure the contribution of those attributes to preferences.
METHODS: A total of 382 people with T2DM were recruited to participate in an internet-based survey consisting of a series of health-related questions, a conjoint exercise and a set of time trade-off items. In the conjoint exercise, respondents were presented with eight pairs of hypothetical GLP-1 profiles, and completed a time-tradeoff exercise for each pair.
RESULTS: The product profile representing liraglutide was preferred by 96% of respondents and resulted in significantly higher health utilities (0.038) than the product profile representing exenatide (0.978 vs. 0.94, p < 0.05). Estimated preference scores from the conjoint analysis revealed that efficacy measured by hemoglobin A(1C) is the most important attribute, followed by nausea, hypoglycemia, and dosing schedule.
LIMITATIONS: On-line participants may not represent 'typical' type 2 diabetes patients, and brief product profiles represented results from clinical trials, not clinical practice
CONCLUSION: Based on the four attributes presented, patients prefer liraglutide over exenatide. Preference is based on superior efficacy and less nausea more than less hypoglycemia and once-daily dosing.
Authors:
Michael Polster; Elaine Zanutto; Susan McDonald; Christopher Conner; Mette Hammer
Related Documents :
8941507 - Coca chewing for exercise: hormonal and metabolic responses of nonhabitual chewers.
8833707 - Endogenous oploid peptides stimulate post-exercise insulin response to glucose in rats.
1186497 - The effect of somatostatin on plasma noradrenaline and plasma adrenaline concentrations...
1514617 - Metabolic regulation in peripheral tissues and transition to increased gluconeogenic mo...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-11-01
Journal Detail:
Title:  Journal of medical economics     Volume:  13     ISSN:  1941-837X     ISO Abbreviation:  J Med Econ     Publication Date:  2010  
Date Detail:
Created Date:  2010-12-08     Completed Date:  2011-05-03     Revised Date:  2013-05-13    
Medline Journal Info:
Nlm Unique ID:  9892255     Medline TA:  J Med Econ     Country:  England    
Other Details:
Languages:  eng     Pagination:  655-61     Citation Subset:  IM    
Affiliation:
National Analysts Worldwide, Philadelphia, PA 19103, USA. mpolster@nationalanalysts.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Diabetes Mellitus, Type 2 / drug therapy*
Drug Administration Schedule
Female
Glucagon-Like Peptide 1 / administration & dosage,  adverse effects,  analogs & derivatives*,  therapeutic use
Hemoglobin A, Glycosylated
Humans
Hypoglycemia / chemically induced
Hypoglycemic Agents / administration & dosage,  adverse effects,  therapeutic use*
Male
Middle Aged
Nausea / chemically induced
Patient Preference*
Peptides / administration & dosage,  adverse effects,  therapeutic use*
Quality of Life
Socioeconomic Factors
Venoms / administration & dosage,  adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents; 0/Peptides; 0/Venoms; 141732-76-5/exenatide; 839I73S42A/liraglutide; 89750-14-1/Glucagon-Like Peptide 1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Low doses of transdermal fentanyl in opioid-naive patients with cancer pain.
Next Document:  The impact of pain on labor force participation, absenteeism and presenteeism in the European Union.